NDAINTRAVENOUSSOLUTION
Approved
Apr 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
7/8 — Comprehensive
AKYNZEO (fosnetupitant and palonosetron) by Helsinn is serotonin 3 receptor antagonists [moa]. Approved for combination with dexamethasone in adults for the prevention of acute, delayed nausea, vomiting associated with initial and 5 more indications. First approved in 2018.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKYNZEO is a fixed-dose combination IV antiemetic containing fosnetupitant (NK1 antagonist) and palonosetron (5-HT3 antagonist) designed to prevent acute and delayed chemotherapy-induced nausea and vomiting (CINV). It is administered with dexamethasone in adults receiving highly emetogenic cancer chemotherapy, offering a single-injection approach to multimodal emesis control.
$0.441MPart D
Peak10.9 years to LOEProduct is at peak commercial maturity with modest Part D penetration; team focus is on optimization and retention rather than expansion.
Mechanism of Action
Serotonin 3 Receptor Antagonists
Pharmacologic Class:
Serotonin-3 Receptor Antagonist
Worked on AKYNZEO at Helsinn? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.